<DOC>
	<DOCNO>NCT01984749</DOCNO>
	<brief_summary>The purpose study demonstrate effect febuxostat prevent cerebral cardiorenovascular event elderly patient hyperuricemia risk cerebral cardiorenovascular disease .</brief_summary>
	<brief_title>Febuxostat Cerebral caRdiorenovascular Events prEvEntion stuDy</brief_title>
	<detailed_description />
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<criteria>( 1 ) Patients 65 year age old enrollment able visit ( 2 ) Patients hyperuricemia , serum uric acid level &gt; 7.0 mg/dL &lt; = 9.0 mg/dL ( 7.0 mg/dL &lt; serum uric acid level &lt; = 9.0 mg/dL ) within 2 month prior enrollment ( 3 ) Patients risk cerebral cardiorenovascular disease ) iv ) ( ) Previous current history hypertension ( ii ) Previous current history type 2 diabetes mellitus ( iii ) Renal disorder ( 30 mL/min/1.73 m2 &lt; = eGFR &lt; 60 mL/min/1.73 m2 within 3 month prior enrollment ) ( iv ) Previous history cerebral cardiorenovascular disease 3 month prior enrollment ( stroke [ cerebral hemorrhage , cerebral infarction , subarachnoid hemorrhage ] , coronary artery disease , vascular disease , cardiac failure ) ( 4 ) Patients personally give write informed consent participate study ( 1 ) Patients gouty tophus , patient subjective symptom gouty arthritis within 1 year prior enrollment ( 2 ) Patients previous history hypersensitivity febuxostat allopurinol ( 3 ) Patients malignant tumor ( 4 ) Patients serious kidney disease , Acute kidney disease , nephrotic syndrome , dialysis patient , kidney transplant patient , eGFR &lt; 30 mL/min/1.73 m2 , etc . ( 5 ) Patients previous history acute coronary syndrome stroke within 3 month prior enrollment ( cerebral hemorrhage , cerebral infarction , subarachnoid hemorrhage ) ( 6 ) Patients &gt; = 50 % increase serum creatinine within 3 month prior enrollment ( 7 ) Patients severe hypertension characterize systolic blood pressure &gt; = 180 mmHg diastolic blood pressure &gt; = 110 mmHg within 3 month prior enrollment ( 8 ) Patients aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) 2 time upper limit normal within 3 month prior enrollment ( 9 ) Patients follow medication enrollment Mercaptopurine hydrate , azathioprine , vidarabine , didanosine ( 10 ) Patients receive follow medication treatment hyperuricemia within 1 month prior enrollment Allopurinol , benzbromarone , probenecid , bucolome , topiroxostat , febuxostat ( 11 ) Patients start , modify dose , discontinue follow medication within 1 month prior enrollment Losartan , irbesartan , fenofibrate , thiazide diuretic , loop diuretic ( 12 ) Patients hormone replacement therapy estrogen ( estrogenic hormone product ) ( 13 ) Patients participate clinical research ( include trial ) within 6 month prior enrollment ( noninterventional observational research exclude ) ( 14 ) Patients otherwise judge principal subinvestigator unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>